Green Cross Corp (006280) - Net Assets
Based on the latest financial reports, Green Cross Corp (006280) has net assets worth ₩1.49 Trillion KRW (≈ $1.01 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩3.19 Trillion ≈ $2.16 Billion USD) and total liabilities (₩1.70 Trillion ≈ $1.15 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 006280 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩1.49 Trillion |
| % of Total Assets | 46.67% |
| Annual Growth Rate | 19.44% |
| 5-Year Change | 16.68% |
| 10-Year Change | 48.44% |
| Growth Volatility | 60.12 |
Green Cross Corp - Net Assets Trend (2003–2024)
This chart illustrates how Green Cross Corp's net assets have evolved over time, based on quarterly financial data. Also explore Green Cross Corp total assets for the complete picture of this company's asset base.
Annual Net Assets for Green Cross Corp (2003–2024)
The table below shows the annual net assets of Green Cross Corp from 2003 to 2024. For live valuation and market cap data, see market cap of Green Cross Corp.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩1.48 Trillion ≈ $1.00 Billion |
-3.82% |
| 2023-12-31 | ₩1.54 Trillion ≈ $1.04 Billion |
-1.71% |
| 2022-12-31 | ₩1.57 Trillion ≈ $1.06 Billion |
+4.46% |
| 2021-12-31 | ₩1.50 Trillion ≈ $1.02 Billion |
+18.16% |
| 2020-12-31 | ₩1.27 Trillion ≈ $860.19 Million |
+7.20% |
| 2019-12-31 | ₩1.18 Trillion ≈ $802.43 Million |
+5.14% |
| 2018-12-31 | ₩1.13 Trillion ≈ $763.21 Million |
+1.58% |
| 2017-12-31 | ₩1.11 Trillion ≈ $751.36 Million |
+4.69% |
| 2016-12-31 | ₩1.06 Trillion ≈ $717.68 Million |
+6.14% |
| 2015-12-31 | ₩997.70 Billion ≈ $676.13 Million |
+8.37% |
| 2014-12-31 | ₩920.63 Billion ≈ $623.90 Million |
+9.68% |
| 2013-12-31 | ₩839.41 Billion ≈ $568.86 Million |
+22.50% |
| 2012-12-31 | ₩685.23 Billion ≈ $464.37 Million |
+8.72% |
| 2011-12-31 | ₩630.28 Billion ≈ $427.13 Million |
+16.24% |
| 2010-12-31 | ₩542.23 Billion ≈ $367.46 Million |
+191.56% |
| 2006-12-31 | ₩185.98 Billion ≈ $126.03 Million |
+27.65% |
| 2005-12-31 | ₩145.70 Billion ≈ $98.74 Million |
+33.73% |
| 2004-12-31 | ₩108.95 Billion ≈ $73.83 Million |
+206.90% |
| 2003-12-31 | ₩35.50 Billion ≈ $24.06 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Green Cross Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 81533563981000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩815.34 Billion | 65.09% |
| Other Components | ₩437.31 Billion | 34.91% |
| Total Equity | ₩1.25 Trillion | 100.00% |
Green Cross Corp Competitors by Market Cap
The table below lists competitors of Green Cross Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Elsight Ltd
AU:ELS
|
$1.06 Billion |
|
Anhui Xinlong Electrical Co Ltd
SHE:002298
|
$1.06 Billion |
|
BioPharma Credit PLC
LSE:BPCR
|
$1.06 Billion |
|
Huizhou China Eagle Electronic Technology Co Ltd
SHE:002579
|
$1.06 Billion |
|
Corbion N.V.
F:CSU
|
$1.06 Billion |
|
Anhui Expressway Company Limited
F:HU7
|
$1.06 Billion |
|
Bank Artos Indonesia Tbk PT
JK:ARTO
|
$1.06 Billion |
|
Baota Industry Co Ltd
SHE:000595
|
$1.06 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Green Cross Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,300,236,293,690 to 1,252,644,924,130, a change of -47,591,369,560 (-3.7%).
- Net loss of 26,280,215,150 reduced equity.
- Dividend payments of 19,532,262,500 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-26.28 Billion | -2.1% |
| Dividends Paid | ₩19.53 Billion | -1.56% |
| Other Changes | ₩-1.78 Billion | -0.14% |
| Total Change | ₩- | -3.66% |
Book Value vs Market Value Analysis
This analysis compares Green Cross Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.25x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.50x to 1.25x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩91141.41 | ₩137100.00 | x |
| 2018-12-31 | ₩92840.80 | ₩137100.00 | x |
| 2019-12-31 | ₩91887.77 | ₩137100.00 | x |
| 2020-12-31 | ₩98002.82 | ₩137100.00 | x |
| 2021-12-31 | ₩111692.86 | ₩137100.00 | x |
| 2022-12-31 | ₩116367.45 | ₩137100.00 | x |
| 2023-12-31 | ₩113924.12 | ₩137100.00 | x |
| 2024-12-31 | ₩109754.26 | ₩137100.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Green Cross Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.56%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 2.19x
- Recent ROE (-2.10%) is below the historical average (8.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 21.09% | 6.90% | 1.19x | 2.58x | ₩3.79 Billion |
| 2004 | 6.37% | 4.78% | 0.57x | 2.36x | ₩-3.86 Billion |
| 2005 | 20.46% | 7.82% | 1.25x | 2.08x | ₩14.90 Billion |
| 2006 | 19.04% | 8.59% | 1.12x | 1.99x | ₩16.52 Billion |
| 2010 | 19.44% | 13.23% | 1.07x | 1.38x | ₩50.84 Billion |
| 2011 | 8.96% | 7.21% | 0.89x | 1.39x | ₩-6.45 Billion |
| 2012 | 7.98% | 6.61% | 0.85x | 1.42x | ₩-13.54 Billion |
| 2013 | 8.51% | 7.89% | 0.80x | 1.34x | ₩-12.24 Billion |
| 2014 | 9.40% | 8.61% | 0.73x | 1.49x | ₩-5.32 Billion |
| 2015 | 9.93% | 9.06% | 0.74x | 1.48x | ₩-713.55 Million |
| 2016 | 6.34% | 5.26% | 0.77x | 1.56x | ₩-36.34 Billion |
| 2017 | 5.12% | 4.13% | 0.76x | 1.64x | ₩-50.77 Billion |
| 2018 | 3.25% | 2.58% | 0.77x | 1.63x | ₩-71.53 Billion |
| 2019 | -0.35% | -0.27% | 0.70x | 1.87x | ₩-108.51 Billion |
| 2020 | 7.25% | 5.39% | 0.70x | 1.92x | ₩-30.80 Billion |
| 2021 | 9.67% | 8.01% | 0.62x | 1.93x | ₩-4.27 Billion |
| 2022 | 4.93% | 3.82% | 0.68x | 1.90x | ₩-67.36 Billion |
| 2023 | -2.05% | -1.64% | 0.62x | 2.03x | ₩-156.66 Billion |
| 2024 | -2.10% | -1.56% | 0.61x | 2.19x | ₩-151.54 Billion |
Industry Comparison
This section compares Green Cross Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $401,390,357,055
- Average return on equity (ROE) among peers: 0.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Green Cross Corp (006280) | ₩1.49 Trillion | 21.09% | 1.14x | $1.06 Billion |
| Dongwha Pharm.Co.Ltd (000020) | $252.93 Billion | 10.38% | 0.28x | $113.83 Million |
| Yuhan Corp. (000100) | $407.93 Billion | 10.79% | 0.55x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 2.42% | 0.28x | $59.61 Million |
| Yuyu Pharma (000220) | $69.50 Billion | 3.97% | 0.28x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $117.04 Billion | 1.10% | 0.32x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $169.10 Billion | -60.53% | 4.10x | $76.14 Million |
| Samil Pharm (000520) | $127.83 Billion | 1.30% | 1.90x | $127.90 Million |
| Donga Socio Holdings (000640) | $875.86 Billion | 17.02% | 0.60x | $427.15 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $476.78 Million |
About Green Cross Corp
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-… Read more